Germany’s IQWiG Pans Sanofi’s Lyxumia For Wrong Comparator Choices
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi’s failure to align its comparator selection with that of Germany’s reimbursement authorities has resulted in dismissal of Lyxumia for diabetes type 2, although the company will have an opportunity to challenge the decision.
You may also be interested in...
Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher
Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.
Lyxumia As Fourth GLP-1 To Market? Not To Worry, Says Zealand CEO
The Danish biotech has partnerships with major players in several therapeutic areas, including a successful tie-up with Sanofi, and is looking to partner some of its other pipeline programs as well.
NICE Scientific Advice Program May Seek Broader Application Through Boosting Regulator Link-Up
NICE’s scientific advice program, now in its third year, may need refocusing and increased co-operation with regulators to appeal to small and medium-sized companies.